Zevra Therapeutics (ZVRA) Non-Current Assets (2014 - 2026)

Zevra Therapeutics has reported Non-Current Assets for 13 years, with the latest figure at $48.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 12052.75% year-over-year to $48.6 million; the trailing twelve-month figure through Mar 2026 stood at $185.3 million (up 46219.0% YoY), and the FY2025 full-year result was $61.7 million, up 12244.8% from the prior year.
• Non-Current Assets for Q1 2026 stood at $48.6 million, down from $61.7 million in the prior quarter.
• The five-year high for Non-Current Assets was $125.7 million in Q1 2022, with the low at $400000.0 in Q1 2025.
• Historically, Non-Current Assets has averaged $42.2 million across 5 years, with a median of $35.6 million in 2022.
• The largest YoY upside for Non-Current Assets was 12244.8% in 2025 against a maximum downside of 99.55% in 2025.
• Zevra Therapeutics' Non-Current Assets stood at $22.5 million in 2022, then slumped by 97.78% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then jumped by 12244.8% to $61.7 million in 2025, then decreased by 21.24% to $48.6 million in 2026.
• The last three Non-Current Assets figures came in at $48.6 million (Q1 2026), $61.7 million (Q4 2025), and $45.0 million (Q3 2025), per Business Quant data.